A/Prof Mikael Hartman, Senior Consultant, Division of General Surgery (Breast and Trauma Surgery), National University Hospital, and Programme Leader for Breast Cancer Prevention Research at NUS Saw Swee Hock School of Public Health, noted that although there is an increase in breast cancer in women aged 50 and above, it is very rare in women below the age of 35. He added that since there are minimal means to prevent the disease, efforts must be focused on finding the disease early as treatments then are less complicated with better outcomes. A/Prof Hartman also shared that he is working with several researchers to develop techniques to test specific risks for the disease.
Channel NewsAsia Lifestyle also cited a novel combined therapy being explored by National University Cancer Institute Singapore for breast
cancer treatment, using letrozole and lenvatinib. The research’s lead
investigator, Prof Lee Soo Chin, Head and Senior Consultant, Department of
Haematology-Oncology, National University Cancer Institute Singapore, said the findings showed that the therapy is
effective in the treatment of breast cancer, even in patients whose disease is
no longer well-controlled by conventional hormone therapy options.
Co-investigator Dr Joline Lim, Consultant Department of Haematology-Oncology,
National University Cancer Institute Singapore, added that a late phase trial is underway to compare the current standard
treatment against the letrozole-lenvatinib combination.Media ArticlesNUH in the NewsNCIS in the NewsNUHS in the News